Bought 11 shares of $PFE @pfizer looks to break Downtrend it's a strong buy! My trade https://twitter.com/MichaelMurphyKO/status/1757063571660251326?t=-HfOsT5D2WKjBDu66NJWlQ&s=19
This day with it followed chart. The high of day hit Downtrend line. Then traded sideways no ways it's testing that double bottom it put in last month. Looks like a strong buy going into week and next.
.@pfizer $PFE At the current valuation, I calculate a growth potential of 20.8% by the end of 2024 and 50.2% by the end of 2025, based on conservative estimates. I, therefore, rate the PFE stock as a "Buy". https://seekingalpha.com/article/4669587-pfizer-stock-its-time-to-buy-the-dip
I hope this U.S. stock futures were flat Tuesday night after the Dow Jones Industrial Average posted its biggest decline since March 2023. Futures tied to the Dow slipped 15 points, or 0.04%. S&P 500 futures inched up 0.02%, and Nasdaq 100 futures added 0.07%. I hope it doesn't show a breaking of triple bottom!!! Hold on folks won't be longer then week before we see where we go!
Try New Site Pfizer: A Cheap Stock Lacking a Catalyst Blue Chip Portfolios Wed, February 14, 2024 at 7:00 AM CST·5 min read In this article: PFE +0.06% Fair Value Estimate UndervaluedSee why Finding stocks that trade at low valuations is fairly easy as there are many companies with weak prospects trading at low valuations. However, many of those companies are cheap for a reason and lack a catalyst to drive a valuation re-rating. Pfizer Inc. (NYSEFE) is a cheap stock based on most conventional metrics. The stock yields 6.10% and trades at just 12.40 times consensus 2024 earnings per share and 10 times consensus 2025 earnings. Warning! GuruFocus has detected 6 Warning Sign with PFE. ADVERTISEMENT The stock has a GF value of approximately $39 per share compared to a current share price of roughly $27. However, I believe the stock lacks any near-term catalyst to drive a closure of this gap. Pfizer: A Cheap Stock Lacking a Catalyst Recent challenges The company has struggled over the past three years as sales of the company's Covid-19 vaccine and related products have declined. 2023 sales came in at approximately $58.50 billion, which represents a roughly 42% decline from 2022 levels. Adjusted earnings per share came in at $1.84, representing a roughly 72% decline from 2022 levels. Excluding the impact of the company's Covid-19-related products (Comirnaty and Paxlovid), revenue grew by 8%. ADVERTISEMENT On March 13, Pfizer announced plans to acquire Seagen in an all-cash deal for roughly $43 billion, or $229 per share. Prior to the announcement of the deal, Seagen shared had been trading at $172 per share. In order to finance this deal, Pfizer issued $31 billion in new unsecured notes and used cash and existing short-term financing from its balance sheet. The transaction was completed in December 2023. Pfizer shares have dropped by roughly 30% since the transaction was first announced. I believe part of the reason for the decline is that shareholders are somewhat skeptical of the large valuation premium paid by the company. Moreover, the financing of the transaction resulted in a significant increase in debt and a more highly levered balance sheet than was previously the case. Pfizer: A Cheap Stock Lacking a Catalyst PFE Data by GuruFocus Pfizer: A Cheap Stock Lacking a Catalyst Revenue and earnings expected to stabilize The company expects 2024 revenue to come between $58.50 billion and $61.50 billion. This is in line with current consensus estimates, which call for revenue to come in close to $60 billion. The company expects adjusted earnings of $2.05 to $2.25 per share, which is slightly below current consensus estimates of $2.41. While a stabilization of financial results is a positive, I do not view it as a catalyst to send shares higher given the company's guidance is broadly in line with consensus estimates. Valuation Perspectives Pfizer's forward price-earnings ratio of 12.40 is cheap relative to the broader market, which trades closer to 22 times forward earnings. However, the company's valuation is somewhat less compelling compared to peers and its own historical norm. ADVERTISEMENT Over the past 10 years, the stock has traded at an average of 15.70 times adjusted earnings. Some of the company's key peers include Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), Astrazeneca (NASDAQ:AZN) and Novartis (NYSE:NVS). These companies trade at approximately 14.90, 7.20, 16.30 and 14.50 times forward earnings respectively. Based on these metrics, despite a very low price-earnings ratio relative to the broader market, I view Pfizer as only modestly attractive relative to historical norms and peers. Thus, I would only consider buying the stock if an upside catalyst were to materialize. Potential upside catalysts One potential upside catalyst for Pfizer would be a potential increase in Covid-19 vaccination rates. Its Covid product, Comirnaty, was the company's best-selling product in the third quarter of 2023, accounting for 37.60% of the total revenue. Just over 505 million doses of its original vaccine were delivered in the U.S. while just 90 million doses of its booster have been delivered in the U.S. A major pickup in cases could result in increased demand for booster shots. However, this seems unlikely given the recent trajectory of interest in Covid-19 vaccines. ADVERTISEMENT Another potential upside catalyst would be successful product launches and sales from the company's oncology pipeline. Pfizer doubled the size of its oncology pipeline when it acquired Seagen. The company believes it can deliver at least eight blockbuster products by 2030. On its third-quarter conference call, the company suggested it believes revenue related to Seagen can reach $10 billion by 2030 from an expected level of $3.10 billion for 2024. This growth is dependent on successful product launches, which can be difficult to predict. Share repurchases would also represent a positive catalyst. The company currently has a share repurchase authorization of $3.30 billion. However, the company has said it does not anticipate any share repurchases in 2024 as it remains focused on debt reduction. Conclusion Pfizer is a cheap stock trading at a valuation well below the broader market. The company has experienced declining revenue and earnings over the past year as Covid-19 product sales have dropped. The company's recent acquisition of Seagen was transformational in nature, but the ultimate success of the deal will depend on pipeline realization. ADVERTISEMENT The stock is currently trading at a modest discount to most peers and at a modest discount to its average historical valuation. However, the stock lacks a near-term catalyst to drive a valuation re-rating. Increased demand for Covid-19 vaccines, strong product launches from the company's oncology pipeline and a potential resumption of share repurchases are all potential catalysts that investors should keep an eye on. That said, I do not view any of these catalysts as particularly likely to emerge over the short term. For these reasons, I view Pfizer as a value stock lacking a catalyst and not a highly attractive investment at current levels. This article first appeared on GuruFocus. PFE +0.06% Terms/Privacy Policy Privacy Dashboard About Our Ads RECOMMENDED STORIES Motley Fool Contrarian Plays: 3 Stocks Going Against the Grain That Could Deliver Huge Gains 1d ago Zacks Cloud Computing ETF (CLOU) Hits New 52-Week High 23h ago The Wall Street Journal AEP Enters Agreement With Icahn Capital 2d ago Zacks 5 Safe Stocks to Buy as Inflation Rattles Wall Street 5h ago Motley Fool 1 Incredibly Cheap Stock to Buy With $500 Right Now 1d ago Zacks Here is What to Know Beyond Why Super Micro Computer, Inc. (SMCI) is a Trending Stock 4h ago Zacks CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? 5h ago Motley Fool A Bull Market Is Here: 2 Super Stocks Down 67% and 46% to Buy Right Now 4h ago Zacks Chimera Investment (CIM) Matches Q4 Earnings Estimates 5h ago Zacks Williams Companies, Inc. (The) (WMB) Reports Q4 Earnings: What Key Metrics Have to Say 4h ago Zacks Barrick Gold (GOLD) Tops Q4 Earnings Estimates 6h ago Zacks Occidental (OXY) to Report Q4 Earnings: What's in Store? 1d ago Barrons.com Blink Charging Stock Soars. A Huge Sales Beat Gives EV Investors Some Hope. 4h ago Bloomberg Lyft’s CEO Says ‘My Bad’ on Margin Error, ‘It Was One Zero’ 30m ago Benzinga Dave Ramsey Calls Out A 61-Year-Old With 'No Money' — 'Broke People Don't Have $26,000 Tractors' 22h ago Motley Fool Palantir Stock Is Going to the Moon Following Its Jaw-Dropping Earnings Report 1d ago Motley Fool Why Kratos Defense & Security Stock Rocketed Higher Today 3h ago CBS MoneyWatch Here's when experts think the Fed could start cutting interest rates 1h ago Motley Fool This Stock Market Indicator Has Been 100% Accurate Since 1957. It Signals a Big Move in the S&P 500 in 2024. 8h ago Benzinga How To Earn $1,000 Per Month From McDonald's Stock 1d ago
Bullish @pfizer $PFE check the chart closed below major moving average high was a downtrend break. Should break Downtrend Friday or Monday!
Considering how many labs are working on covid-19 variants, including increase of function, Pfizer seems like a good bet. It didn't help all that much in the last pandemic but it will be used heavily in the next.
.@pfizer $PFE has received a consensus rating of “Mod Buy” from analysts, and its mean target price of $36.11 is 33% higher than closing price. 18 analysts covering the stock, only 7 rate it as a “Strong Buy,” and 1 as a “Mod Buy.” The remaining 10 analysts rate stock as a “Hold
https://finance.yahoo.com/news/decoding-pfizer-inc-pfe-strategic-050741922.html On February 22, 2024, Pfizer Inc, a global leader in biopharmaceuticals, filed its annual 10-K report, revealing a financial landscape shaped by both robust sales in its prescription drugs and vaccines and the challenges of a dynamic market. Despite a decrease in total revenues to $58.5 billion, a 42% drop from the previous year, largely due to the operational wind-down of COVID-19 product sales, Pfizer's financial tables reflect the company's enduring strength in its core offerings. The company's strategic acquisitions, such as the transformative purchase of Seagen, and its commitment to R&D, signal a focused drive towards future growth and innovation. Warning! GuruFocus has detected 6 Warning Sign with PFE. Decoding Pfizer Inc (PFE): A Strategic SWOT Insight As we delve into the SWOT analysis of Pfizer Inc (NYSEFE), we will explore the company's internal strengths and weaknesses, as well as the external opportunities and threats that could influence its trajectory in the pharmaceutical industry.
BIOTECH AND PHARMA | STREET NOTES Pfizer Stock Has 29% Upside, Says a New Bull Guggenheim analysts initiated coverage of drug firm Pfizer at Buy with a $36 price target. Shares have lagged behind the market in recent years. By Emily Dattilo Updated Feb. 23, 2024 12:21 pm ET / Original Feb. 23, 2024 11:59 am ET Pfizer has more going for it than just Covid-19 vaccines, argue Guggenheim analysts led by Vamil Divan who initiated coverage with a Buy rating and $36 price target in a Thursday report. Pfizer stock was up 1.7% to $28.01, while the S&P 500 gained 0.2% in Friday trading. Guggenheim’s price target implies nearly 29% of upside for the stock price. Shares... Privacy Notice Cookie Notice Copyright Policy Data Policy Your Ad Choices Subscriber Agreement & Terms of Use Copyright © 2024 Dow Jones & Company, Inc. All Rights Reserved. THANKS FOR READING To continue reading and get full access to market-moving insights, become a Barron's subscriber today. SUBSCRIBE NOW: $1 PER WEEK JOIN NOWLOG IN
If youre trading going against the trend most often than not will end bad. If youre investing a dif story. At present level I think PFE is not an expensive. Maybe time will teach me that price was not as cheap as I was thinking.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire Tue, March 5, 2024 at 9:00 AM CST·2 min read In this article: PFE +0.73% Recommendation Rating Buy NEW YORK, March 05, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer & President, Pfizer Research and Development, at the Leerink Partners Global Biopharma Conference 2024 on Tuesday, March 12, 2024 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. ADVERTISEMENT The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
